Scott Hirsch

Scott Hirsch has over 20 years of work experience in the biotechnology and pharmaceutical industry. Scott is currently the CEO of Firefly Biologics, a position they have held since April 2023. Prior to this, they worked at Allakos Inc as the Chief Operating Officer (Immunology) from 2019 to March 2023, and as the Senior Vice President of Strategy & Operations (Immunology) from 2019 to December 2022. Before joining Allakos Inc, they held various roles at AbbVie, including Site Head, South San Francisco (Oncology) in 2019 and Head of Portfolio Management (Oncology) from 2016 to 2019. Scott also served as the Vice President of Portfolio Management at Stemcentrx, Inc. in 2016 before it was acquired by AbbVie. Prior to that, they worked at Genentech in different roles, including Senior Director, Lifecycle Leader (Polivy), Director, Pipeline & Portfolio Planning (Oncology), and Associate Director, Pipeline & Portfolio Planning (Oncology). Scott also held marketing and sales positions at Genentech, including Group Product Manager, Marketing (Actemra) and Clinical Specialist, Sales (Rituxan & Xolair). Before entering the biotech industry, they worked as a Senior Consultant and Consultant in the Strategy Practice at Capgemini from 2000 to 2003.

Scott Hirsch attended Amherst College, where they earned a Bachelor's degree. Afterward, they went on to study at Harvard Business School, where they obtained a Master in Business Administration (MBA) degree.